Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 231-236

  van Leuven, Sander I ^a   van Wijk, Diederik F ^a   Volger, Oscar L ^b   de Vries, Jean Paul P M ^c   van der Loos, Chris M ^a   de Kleijn, Dominique V P ^d   Horrevoets, Anton J G ^b   Tak, Paul P ^a   van der Wal, Allard C ^a   de Boer, Onno J ^a   Pasterkamp, Gerard ^d   Hayden, Michael R ^e   Kastelein, John J P ^a   Stroes, Erik S ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Atherosclerosis; Endarterectomy; Inflammation; Mycophenolate mofetil

Indexed keywords

CD68 ANTIGEN; CD69 ANTIGEN; METALLOPROTEINASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOPONTIN; PLACEBO; TRANSCRIPTION FACTOR FOXP3; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; AGED; ARTICLE; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MACROPHAGE; MALE; MICROARRAY ANALYSIS; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANALOGS AND DERIVATIVES; ATHEROSCLEROSIS; CAROTID STENOSIS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY;

AGED; ATHEROSCLEROSIS; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; T-LYMPHOCYTES, REGULATORY;

EID: 77954314887     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.01.043     Document Type: Article

References (32)

1. Libby P. Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874.
2. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110(2):227-239.
3. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21):2195-2207.
4. Kuiper J., van Puijvelde G.H., van Wanrooij E.J., et al. Immunomodulation of the inflammatory response in atherosclerosis. Curr Opin Lipidol 2007, 18(5):521-526.
5. van Leuven S.I., Kastelein J.J., D'Cruz D.P., Hughes G.R., Stroes E.S. Atherogenesis in rheumatology. Lupus 2006, 15(3):117-121.
6. Allison A.C. Mechanisms of action of mycophenolate mofetil. Lupus 2005, 14(Suppl. 1):s2-s8.
7. van Leuven S.I., Kastelein J.J., Allison A.C., Hayden M.R., Stroes E.S. Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles?. Cardiovasc Res 2006, 69(2):341-347.
8. Baldi P., Long A.D. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 2001, 17(6):509-519.
9. Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. Bioinformatics and computational biology solutions using R and bioconductor 2005:397-420.
10. Subramanian A., Tamayo P., Mootha V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550.
11. Hosono M., de Boer O.J., van der Wal A.C., et al. Increased expression of T cell activation markers (CD25, CD26, CD40L and CD69) in atherectomy specimens of patients with unstable angina and acute myocardial infarction. Atherosclerosis 2003, 168(1):73-80.
12. McInnes I.B., Leung B.P., Sturrock R.D., Field M., Liew F.Y. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997, 3(2):189-195.
13. de Boer O.J., van der Meer J.J., Teeling P., van der Loos C.M., van der Wal A.C. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007, 2(1):e779.
14. it-Oufella H., Salomon B.L., Potteaux S., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12(2):178-180.
15. + regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27(4):893-900.
16. + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108(1):390-399.
17. Huang Y., Liu Z., Huang H., Liu H., Li L. Effects of mycophenolic acid on endothelial cells. Int Immunopharmacol 2005, 5(6):1029-1039.
18. Hou M., Peng J., Shi Y., et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003, 70(6):353-357.
19. Wenzl H.H., Hinterleitner T.A., Aichbichler B.W., Fickert P., Petritsch W. Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome. Aliment Pharmacol Ther 2004, 19(4):427-434.
20. van Hest R.M., Doorduijn J.K., de Winter B.C., et al. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit 2007, 29(3):353-360.
21. Ng J., Rogosheske J., Barker J., Weisdorf D., Jacobson P.A. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit 2006, 28(3):394-401.
22. Okamura A., Yamamori M., Shimoyama M., et al. Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation. Int J Hematol 2008, 88(1):104-110.
23. O'Brien E.R., Garvin M.R., Stewart D.K., et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994, 14(10):1648-1656.
24. Isoda K., Kamezawa Y., Ayaori M., Kusuhara M., Tada N., Ohsuzu F. Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 2003, 107(5):679-681.
25. Matsui Y., Rittling S.R., Okamoto H., et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003, 23(6):1029-1034.
26. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007, 27(11):2302-2309.
27. Olson F.J., Schmidt C., Gummesson A., et al. Circulating matrix metalloproteinase 9 levels in relation to sampling methods, femoral and carotid atherosclerosis. J Intern Med 2008, 263(6):626-635.
28. Barish G.D., Atkins A.R., Downes M., et al. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci USA 2008, 105(11):4271-4276.
29. Babaev V.R., Yancey P.G., Ryzhov S.V., et al. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005, 25(8):1647-1653.
30. Gibson W.T., Hayden M.R. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann NY Acad Sci 2007, 1110:209-221.
31. Shaw J.A., Bobik A., Murphy A., et al. Infusion of Reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008, 103(10):1084-1091.
32. Su A.I., Wiltshire T., Batalov S., et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004, 101(16):6062-6067.